Nary a day goes by that the plaintiffs’ bar is not busily at work initiating a new mass tort action. Some cases expand on ...

The theory against these was launched from the Zantac claims, which are still clogging court calendars. In early October, ...

Requesting deletion closes your account permanently and prevents your data from being used in further research (existing ...

Aims: Non-steroidal anti-inflammatory drugs have been associated with increased risk of congestive heart failure (CHF). We aimed to assess the impact of treatment with etoricoxib or diclofenac on ...

Glaxo-Smith Kline, Hoechst Marion Roussel, Hoffman LaRoche, Janssen-Ortho, Oscient Pharmaceuticals, Merck Frosst, Pfizer, Rhone-Poulenc Rorer, Smith-Kline Beecham, Wyeth-Ayerst, YM Biosciences ...

GSK’s 3 billion pounds sterling peak sales goal for its multiple myeloma drug Blenrep appears increasingly attainable thanks ...

GSK Plc said its blood cancer drug significantly reduced the risk of death when combined with another cancer treatment, ...

GSK is carving out a niche for Blenrep in the second-line multiple myeloma setting, for which it projects a multi-blockbuster ...

In a move to safeguard its dominant position in cancer treatments, Merck agreed to license a drug from a Chinese company ...

GSK is the latest to turn its back on prominent industry lobbying group Biotechnology Innovation Organization (BIO), ...

GSK's phase 3 trial shows Blenrep combined with BorDex improves overall survival in relapsed multiple myeloma.

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...